New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Innovative approach for detecting pre-cancerous lesions using large, high-res images

Innovative approach for detecting pre-cancerous lesions using large, high-res images

A new study presents an innovative approach to the crucial detection of pre-cancerous lesions using large, high-res images. A team of researchers from Portugal developed a machine learning solution th
World medicine November 21,2023
Innovative approach for detecting pre-cancerous lesions using large, high-res images

Innovative approach for detecting pre-cancerous lesions using large, high-res images

A new study presents an innovative approach to the crucial detection of pre-cancerous lesions using large, high-res images. A team of researchers from Portugal developed a machine learning solution th
World medicine November 21,2023
MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patie
World medicine November 21,2023
MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patie
World medicine November 21,2023
NCCN guidelines establish an equitable standard of care for cancer outcomes

NCCN guidelines establish an equitable standard of care for cancer outcomes

Today, the National Comprehensive Cancer Network®(NCCN®)-;an alliance of leading cancer centers-;convened a policy summit to examine how geography impacts cancer outcomes.NCCN Chief Executive Of
World medicine November 21,2023
NCCN guidelines establish an equitable standard of care for cancer outcomes

NCCN guidelines establish an equitable standard of care for cancer outcomes

Today, the National Comprehensive Cancer Network®(NCCN®)-;an alliance of leading cancer centers-;convened a policy summit to examine how geography impacts cancer outcomes.NCCN Chief Executive Of
World medicine November 21,2023
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 5, 2023Caroline SeymourThe addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurre
World medicine November 21,2023
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 5, 2023Caroline SeymourThe addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurre
World medicine November 21,2023
Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Although redlining was outlawed more than 50 years ago, new research shows that people today who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical
World medicine November 21,2023
Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Although redlining was outlawed more than 50 years ago, new research shows that people today who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical
World medicine November 21,2023
Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

June 13, 2023Ashling WahnerThe combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered a
World medicine November 21,2023
Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

June 13, 2023Ashling WahnerThe combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered a
World medicine November 21,2023
The SWOG Cancer Research Network trial revealed potential new treatments for stage 3 or 4 classical Hodgkin lymphoma

The SWOG Cancer Research Network trial revealed potential new treatments for stage 3 or 4 classical Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (
World medicine November 21,2023
The SWOG Cancer Research Network trial revealed potential new treatments for stage 3 or 4 classical Hodgkin lymphoma

The SWOG Cancer Research Network trial revealed potential new treatments for stage 3 or 4 classical Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (
World medicine November 21,2023
Case Study Shows That Drug Sensitivity Testing Could Help Personalize Chronic Lymphocytic Leukemia Treatment Selection

Case Study Shows That Drug Sensitivity Testing Could Help Personalize Chronic Lymphocytic Leukemia Treatment Selection

June 7, 2023Fox Chase Cancer CenterResearchers at Fox Chase Cancer Center have developed a model that mimics patients’ tumor microenvironment that they believe has the potential to inform therapeutic
World medicine November 21,2023
Case Study Shows That Drug Sensitivity Testing Could Help Personalize Chronic Lymphocytic Leukemia Treatment Selection

Case Study Shows That Drug Sensitivity Testing Could Help Personalize Chronic Lymphocytic Leukemia Treatment Selection

June 7, 2023Fox Chase Cancer CenterResearchers at Fox Chase Cancer Center have developed a model that mimics patients’ tumor microenvironment that they believe has the potential to inform therapeutic
World medicine November 21,2023
The accuracy of prostate-specific antigen (PSA)

The accuracy of prostate-specific antigen (PSA)

The accuracy of prostate-specificantigen(PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with
World medicine November 21,2023
The accuracy of prostate-specific antigen (PSA)

The accuracy of prostate-specific antigen (PSA)

The accuracy of prostate-specificantigen(PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with
World medicine November 21,2023
Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with
World medicine November 21,2023
Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com